Published in Mol Pharm on May 06, 2013
Nanostructures: a platform for brain repair and augmentation. Front Syst Neurosci (2014) 0.89
Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-hydroxy-NBP and 10-hydroxy-NBP, across the rat blood-brain barrier. Acta Pharmacol Sin (2015) 0.88
Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma. Drug Des Devel Ther (2015) 0.81
New engineered antibodies against prions. Bioengineered (2013) 0.75
Development and Characterization of Methylene Blue Oleate Salt-Loaded Polymeric Nanoparticles and their Potential Application as a Treatment for Glioblastoma. J Nanomed Nanotechnol (2017) 0.75
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med (2011) 2.51
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev (2002) 2.29
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther (2012) 2.03
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs (2011) 1.66
Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies. J Med Chem (2013) 1.49
A strategy for risk mitigation of antibodies with fast clearance. MAbs (2013) 1.42
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41
Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem (2011) 1.40
Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos (2010) 1.38
Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem (2010) 1.32
Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol (2010) 1.27
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol (2012) 1.25
Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol (2005) 1.22
Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J (2012) 1.20
Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos (2004) 1.13
Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet (2011) 1.09
Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res (2005) 1.06
Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res (2003) 1.04
Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med (2013) 0.97
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem (2012) 0.96
Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs (2012) 0.96
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther (2013) 0.94
Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med (2012) 0.92
Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J (2012) 0.92
Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol (2012) 0.92
Soluble Fc fusion proteins for biomedical research. Methods Mol Biol (2007) 0.91
Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res (2007) 0.90
Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res (2008) 0.90
Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology. Ther Deliv (2011) 0.89
Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. PLoS One (2011) 0.89
Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood (2003) 0.89
Delivery of tea polyphenols to the oral cavity by green tea leaves and black tea extract. Cancer Epidemiol Biomarkers Prev (2004) 0.89
Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues. Mol Pharm (2014) 0.88
Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res (2005) 0.87
Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst (2003) 0.87
131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm (2006) 0.87
Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res (2003) 0.86
Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem (2008) 0.86
Development and evaluation of a novel method for preclinical measurement of tissue vascular volume. Mol Pharm (2010) 0.85
Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid Hybridomics (2003) 0.84
Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. Cancer Biother Radiopharm (2007) 0.83
Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies. Pharm Res (2012) 0.83
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett (2010) 0.82
Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett (2010) 0.81
LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother (2003) 0.80
Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins. Hybrid Hybridomics (2002) 0.80
H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models. J Immunother (2006) 0.79
Cytoreductive chemotherapy improves the biodistribution of antibodies directed against tumor necrosis in murine solid tumor models. Mol Cancer Ther (2013) 0.78
chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors. Hybrid Hybridomics (2004) 0.78
An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2. Br J Pharmacol (2013) 0.78
Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys. Pharm Res (2014) 0.78
RA8, a human anti-CD25 antibody against human Treg cells. Hybridoma (Larchmt) (2007) 0.78
Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Cancer Biother Radiopharm (2003) 0.77
Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. MAbs (2013) 0.76
B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother (2006) 0.76
Neotrofin increases heme oxygenase-1 selectively in neurons. Brain Res (2003) 0.75
Vascular physiology and protein disposition in a preclinical model of neurodegeneration. Mol Pharm (2013) 0.75